CD40 and familial pancreatic carcinoma: demonstrated IRE-ablation combined with TLR7 agonist/PD-1 blockade (53) or CD40 agonist (56) improved the therapeutic effect on growth inhibition of KPC pancreatic cancer (~5 mm) by modulating the TME.